Johannes Czernin

About

Dr. Johannes Czernin received his MD degree from the University of Vienna in 1983. He was board certified in Internal Medicine in Austria in 1989 and in Nuclear Medicine in the USA in 1996. In 1996, he was named Director of Nuclear Medicine at the David Geffen School of Medicine at UCLA and currently serves as the Chief of the Ahmanson Translational Theranostics Division at UCLA. The division includes the Nuclear Medicine Clinic, a clinical imaging research program, a drug and probe development program with a strong underpinning in tumor biology, and a preclinical imaging center. It collaborates within the department of molecular and medical pharmacology and across several other departments including medicine, surgery, radiology, neurology, and pathology. Dr. Czernin has over 25 years of experience in preclinical molecular imaging and molecular radiotherapy. He is currently the Editor-in-Chief of the Journal of Nuclear Medicine and is a past president of the Academy of Molecular Imaging. He has published more than 280 peer-reviewed research papers.

Research topics

• Medicine
• Internal medicine
• Nuclear medicine
• Oncology
• Computer Science
• Pathology
• Cancer research
• Urology
• Radiology
• Computer Security

Selected publications

• E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET

  European Journal of Nuclear Medicine and Molecular Imaging · 2021 · 351 citations

  RATIONALE: The development of consensus guidelines for interpretation of Prostate-Specific Membrane Antigen (PSMA)-Positron Emission Tomography (PET) is needed to provide more consistent reports in clinical practice. The standardization of PSMA-PET interpretation may also contribute to increasing the data reproducibility within clinical trials. Finally, guidelines in PSMA-PET interpretation are needed to communicate the exact location of findings to referring physicians, to support clinician the…

  DOI

• Diagnostic Accuracy of ⁶⁸Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection

  JAMA Oncology · 2021 · 334 citations

  IMPORTANCE: The presence of pelvic nodal metastases at radical prostatectomy is associated with biochemical recurrence after prostatectomy. OBJECTIVE: To assess the accuracy of prostate-specific membrane antigen (PSMA) 68Ga-PSMA-11 positron emission tomographic (PET) imaging for the detection of pelvic nodal metastases compared with histopathology at time of radical prostatectomy and pelvic lymph node dissection. DESIGN, SETTING, AND PARTICIPANTS: This investigator-initiated prospective multicen…

  DOI

• Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study

  Journal of Nuclear Medicine · 2022 · 134 citations

  Lu-PSMA in men with mCRPC. PSA + RECIP may be used as a novel composite endpoint in mCRPC clinical trial design.

  DOI

• Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification

  Prostate Cancer and Prostatic Diseases · 2023 · 128 citations

  BACKGROUND: Nearly one-third of patients with prostate cancer (PCa) experience biochemical recurrence (BCR) after primary definitive treatment. BCR increases the risk of distant metastasis and mortality in patients with prognostically unfavorable features. These patients are best managed with a tailored treatment strategy incorporating risk stratification using clinicopathological factors, next-generation imaging, and genomic testing. OBJECTIVE: This narrative review examines the utility of risk…

  PublisherOA PDFDOI

• Head-to-Head Comparison of⁶⁸Ga-PSMA-11 PET/CT and mpMRI with a Histopathology Gold Standard in the Detection, Intraprostatic Localization, and Determination of Local Extension of Primary Prostate Cancer: Results from a Prospective Single-Center Imaging Trial

  Journal of Nuclear Medicine · 2021 · 128 citations

  PSMA PET/CT and mpMRI have similar accuracy in the detection and intraprostatic localization of prostate cancer foci. mpMRI performs better in identifying EPE and SVI. For the T-staging evaluation of intermediate to high-risk prostate cancer, mpMRI should still be considered the imaging modality of reference. Whenever available, PSMA PET/MRI or the coregistration or fusion of PSMA PET/CT and mpMRI (PSMA PET/CT + mpMRI) should be used as it improves tumor extent delineation.

  PublisherOA PDFDOI

Recent grants

• NIH Grant R01CA160770

  NIH · $1.8M · 2014

• NIH Grant P01CA132681

  NIH · $28.7M · 2016

• Cancer Molecular Imaging, Nanotechnology, and Theranostics (CMINT)

  NIH · $65.6M · 1996–2030

Frequent coauthors

• Jérémie Calais

  Molecular Theranostics (United States)

  245 shared

• Caius G. Radu

  University of the Witwatersrand

  164 shared

• Ken Herrmann

  143 shared

• Wolfgang P. Fendler

  University of Duisburg-Essen

  137 shared

• Matthias Eiber

  109 shared

• Michael E. Phelps

  104 shared

• Martin Allen-Auerbach

  Molecular Theranostics (United States)

  89 shared

• Matthew B. Rettig

  72 shared

Awards & honors

• Past president of the Academy of Molecular Imaging
• Editor-in-Chief of the Journal of Nuclear Medicine

Similar researchers at University of California, Los Angeles

• Timothy Cloughesyh-173
• Daniel H. Silvermanh-85
• Jamshid Maddahih-73